Mabpharm Limited (HKG:2181)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.4100
+0.0050 (1.23%)
At close: Mar 6, 2026
Market Cap1.69B +41.4%
Revenue (ttm)464.53M +179.6%
Net Income-30.11M
EPS-0.01
Shares Out4.12B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume42,000
Average Volume101,900
Open0.4100
Previous Close0.4050
Day's Range0.4100 - 0.4100
52-Week Range0.3500 - 0.9400
Beta0.94
RSI23.87
Earnings DateMar 24, 2026

About Mabpharm

Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China. The company offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 383
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2181
Full Company Profile

Financial Performance

In 2024, Mabpharm's revenue was 258.23 million, an increase of 196.27% compared to the previous year's 87.16 million. Losses were -127.95 million, -38.89% less than in 2023.

Financial numbers in CNY Financial Statements